Robert J Fox, Ludwig Kappos. Show Affiliations »
Abstract
Mesh： See more » Antibodies, Monoclonal/administration & dosageAntibodies, Monoclonal/adverse effectsAntibodies, Monoclonal, HumanizedAutoimmunity/drug effectsAutoimmunity/immunologyCentral Nervous System/drug effectsCentral Nervous System/immunologyCentral Nervous System/pathologyChemotaxis, Leukocyte/drug effectsChemotaxis, Leukocyte/immunologyClinical Trials as Topic/statistics & numerical dataDrug Administration ScheduleHumansImmunologic Factors/administration & dosageImmunologic Factors/adverse effectsIntegrin alpha4beta1/drug effectsIntegrin alpha4beta1/immunologyLeukocytes/drug effectsLeukocytes/immunologyMultiple Sclerosis/drug therapyMultiple Sclerosis/immunologyMultiple Sclerosis/pathologyNatalizumabRecurrenceSubstance Withdrawal Syndrome/immunologySubstance Withdrawal Syndrome/pathologySubstance Withdrawal Syndrome/physiopathologyTreatment Outcome
Substances： See more » Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedImmunologic FactorsIntegrin alpha4beta1Natalizumab
Year: 2008 PMID： 18362270 DOI： 10.1212/01.wnl.0000306415.37679.5a
Source DB: PubMed Journal: Neurology ISSN： 0028-3878 Impact factor: 9.910